Quick Answer
TG THERAPEUTICS, INC. reported R&D Expense of $160.22 million for fiscal year 2025.
TG THERAPEUTICS, INC. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $160.22M | +69.9% |
| 2024 | $94.29M | +23.8% |
| 2023 | $76.19M | -39.2% |
| 2022 | $125.35M | -43.7% |
| 2021 | $222.58M | +34.2% |
| 2020 | $165.90M | +7.6% |
| 2019 | $154.18M | -3.3% |
| 2018 | $159.39M | +55.5% |
| 2017 | $102.53M | +48.1% |
| 2016 | $69.23M | +45.1% |
| 2015 | $47.71M | +19.0% |
| 2014 | $40.09M | +193.4% |
| 2013 | $13.66M | -35.0% |
| 2012 | $21.03M | +6325.0% |
| 2011 | $327.3K | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $40.88M | +103.0% | +28.6% |
| June 30, 2025 | $31.78M | +81.0% | -31.4% |
| March 31, 2025 | $46.36M | +41.7% | +130.2% |
| September 30, 2024 | $20.14M | +36.5% | +14.7% |
| June 30, 2024 | $17.56M | -37.6% | -46.3% |
| March 31, 2024 | $32.72M | +106.2% | +121.8% |
| September 30, 2023 | $14.75M | -29.1% | -47.5% |
| June 30, 2023 | $28.12M | +4.6% | +77.2% |
- TG THERAPEUTICS, INC. showed an increase of +69.9% in R&D Expense compared to the prior fiscal year.
- Over the 2011–2025 period, TG THERAPEUTICS, INC.’s r&d expense has grown by 48853.0% (from $327.3 thousand to $160.22 million).
- The most recent figure is from TG THERAPEUTICS, INC.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 27, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: